Lexicon Pharmaceuticals, Inc.
LXRX Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024. In the quarter to June 2026, revenue fell 97.6%, EPS fell 800.0%, free cash flow fell 154.1% and total debt fell 8.32%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow LXRX
Lexicon Pharmaceuticals, Inc. (LXRX) Piotroski F-score
Lexicon Pharmaceuticals, Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (1.00) |
| FY2024 | 5 | 3.00 |
| FY2023 | 2 | 0.00 |
| FY2022 | 2 | (1.00) |
| FY2021 | 3 | 2.00 |
| FY2020 | 1 | (6.00) |
| FY2019 | 7 | 6.00 |
| FY2018 | 1 | (1.00) |
| FY2017 | 2 | 1.00 |
| FY2016 | 1 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (20.83%) | (75.93%) | Fail | 0 |
| Positive operating cash flow | (67.85m) | (178.78m) | Fail | 0 |
| Rising return on assets | (20.83%) | (75.93%) | Pass | 1 |
| Cash flow above net income | (17.51m) | 21.62m | Fail | 0 |
| Falling long-term leverage | 0.20 | 0.38 | Pass | 1 |
| Rising current ratio | 4.88 | 5.44 | Fail | 0 |
| No new shares issued | 363,053,000 | 320,031,000 | Fail | 0 |
| Rising gross margin | 99.45% | 98.02% | Pass | 1 |
| Rising asset turnover | 0.21 | 0.12 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| IVA Inventiva S.A. Sponsored ADR compare | 4 |
| LXRX Lexicon Pharmaceuticals, Inc. | 4 |
| FDMT 4D Molecular Therapeutics, Inc. compare | 4 |
| OABI OmniAb, Inc. compare | 2 |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| SANA Sana Biotechnology, Inc. compare | — |
| ACHV Achieve Life Sciences, Inc. compare | — |
| IMMX Immix Biopharma, Inc. compare | — |
| ANNX Annexon, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover